Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | Vice Chairman | May 23, 2022 | May 25, 2022 |
| Avantor, Inc.AVTR · Entity 3546 | Director | May 07, 2026 | May 11, 2026 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director · Chief Executive Officer | July 28, 2026 | July 30, 2026 |
| Viatris IncVTRS · Entity 3277 | Director | March 06, 2026 | March 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date May 23, 2022 · Filed May 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 152,103 |
Ending reported balance
After 2022-05-23 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2022-05-23 · Exercise / conversion · Acquired 46,320 · Balance 198,423 Row 2 · 2022-05-23 · Exercise / conversion · Acquired 11,742 · Balance 210,165 Row 3 · 2022-05-23 · Exercise / conversion · Acquired 21,739 · Balance 231,904 Row 4 · 2022-05-23 · Sale · Disposed 68,196 · Balance 163,708 F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.13 to $151.12 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2022-05-23 · Sale · Disposed 11,605 · Balance 152,103 F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.13 to $151.58 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.36 · Expires 2028-02-14 | Direct | 0 |
Reported balance
After 2022-05-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-23 · Exercise / conversion · Disposed 46,320 · Balance 0 F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $93.50 · Expires 2030-02-19 | Direct | 38,188 |
Reported balance
After 2022-05-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-23 · Exercise / conversion · Disposed 11,742 · Balance 38,188 F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $105.92 · Expires 2031-02-17 | Direct | 43,478 |
Reported balance
After 2022-05-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-05-23 · Exercise / conversion · Disposed 21,739 · Balance 43,478 F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.13 to $151.12 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.13 to $151.58 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
Avantor, Inc.
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,821 |
Reported balance
After 2026-05-07 transaction · row 1
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 25,270 · Balance 85,821 F1: Reflects a grant of restricted stock units that vests on May 07, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units that vests on May 07, 2027.
Sarepta Therapeutics, Inc.
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 756,104 |
Reported balance
After 2026-07-28 transaction · row 1
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 756,104 · Balance 756,104 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in substantially equal installments on an annual basis over four years from the date of grant, subject to the Reporting Person's continued employment. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.74 · Expires 2036-07-28 | Direct | 2,224,342 |
Reported balance
After 2026-07-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-28 · Grant · Acquired 2,224,342 · Balance 2,224,342 F2: Represents the date upon which the first twenty-five percent of the option granted vests. 1/48th of the total granted option vests and becomes exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continued employment. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in substantially equal installments on an annual basis over four years from the date of grant, subject to the Reporting Person's continued employment.
F2: Represents the date upon which the first twenty-five percent of the option granted vests. 1/48th of the total granted option vests and becomes exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continued employment.
Viatris Inc
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,031 |
Ending reported balance
After 2026-03-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-06 · Exercise / conversion · Acquired 25,112 · Balance 25,112 Row 2 · 2026-03-06 · Exercise / conversion · Acquired 919 · Balance 26,031 F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-06 · Exercise / conversion · Disposed 25,112 · Balance 0 F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,890 |
Reported balance
After 2026-03-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-06 · Grant · Acquired 15,890 · Balance 15,890 F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-06 · Exercise / conversion · Disposed 918.455 · Balance 0 F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on May 12, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. |
Filing footnotes · ownership attribution and instrument terms
F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026.
F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on May 12, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11.
F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 29, 2016 Filed Mar 2, 2016 22:26 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 8,053 | $56.00 | $450,968.00 |
DisclosureSEC source: 0001179110-16-020685 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,856 Read SEC document |
| February 18, 2016 Filed Feb 22, 2016 22:37 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 91,990 | $0.00 Strike: $54.86 | $0.00 |
DisclosureSEC source: 0001179110-16-019789 · edgar.xml · derivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,990 Underlying: Common stock · 91,990 shares Expires 2026-02-17 F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,664 on 02/18/2017, 30,663 on 02/18/2018, and 30,663 on 02/18/2019. Read SEC document |
| February 18, 2016 Filed Mar 2, 2016 22:26 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 91,990 | $0.00 Strike: $54.86 | $0.00 |
DisclosureSEC source: 0001179110-16-020685 · edgar.xml · derivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,990 Underlying: Common stock · 91,990 shares Expires 2026-02-17 Read SEC document |
| June 02, 2015 Filed Jun 4, 2015 21:37 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 21,576 | $66.93 | $1,444,081.68 |
DisclosureSEC source: 0001179110-15-009191 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,909 Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:13 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 104,480 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001179110-15-003167 · edgar.xml · derivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,480 Underlying: Common stock · 104,480 shares Expires 2025-02-18 F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 34,827 on 02/19/2016, 34,826 on 02/19/2017, and 34,826 on 02/19/2018. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:13 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 52,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003167 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,485 F1 · shares: This stock represents performance vested restricted stock under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have a stock withheld for tax purposes. Read SEC document |
| June 02, 2014 Filed Jun 4, 2014 21:51 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 74,309 | $0.00 Strike: $54.44 | $0.00 |
DisclosureSEC source: 0001179110-14-009765 · edgar.xml · derivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,309 Underlying: Common stock · 74,309 shares Expires 2024-06-01 F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,770 on 06/02/2015, 24,769 on 06/02/2016, and 24,770 on 06/02/2017. Read SEC document |
| June 02, 2014 Filed Jun 4, 2014 21:51 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 141,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-009765 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,625 F1 · shares: This stock represents performance vested restricted stock under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have a stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.